Ventas Inc.: A Must-Have Healthcare REIT

Ventas is an interesting income vehicle for investors seeking exposure to the megatrend of rising senior healthcare demand and also enjoy a high dividend yield.

Jul 10, 2014 at 10:33AM

Source: Company

Ventas (NYSE:VTR) allows investors to play one of the most convincing megatrends in our society: Rising health care costs associated with a rising share of elderly in our total population. This trend means growing profits for health care-focused real estate investment trusts.

Ventas is an easy sell. Besides fundamental secular tailwinds stemming from an aging population, an investment in Ventas allows investors to access a superior funds from operation (FFO) and dividend stream, which could receive further boosts from Ventas' acquisition hunger.

The health care REIT has a vast property portfolio across the health care spectrum including senior housing properties, medical office buildings, hospitals and others. Ventas currently owns properties across the United States, Canada and the United Kingdom and is one of the largest theme-focused REITs in the sector with a market capitalization of nearly $19 billion.


Source: Ventas Investor Presentation June 2014

At the end of the first quarter of 2014, Ventas owned 1,473 properties of which 713 related to senior housing communities, 375 were skilled nursing facilities, 327 were medical office buildings, 47 were U.S. hospitals and 11 were other institutions.

Healthcare demand for senior citizens is almost set to increase over the next two to three decades. With improvements in medical treatments and longer life expectancies, the age cohort 75+ is one of the fastest growing segments of the population.

With an increasing share of older people as part of the total population in the next couple of decades, secular tailwinds should substantially support the earnings and cash flow picture of health care-focused REITs such as Ventas which invest today.

Acquisition hunger
Since 2011, Ventas has invested nearly $16 billion in acquisitions and its hunger for acquisition-fueled growth is not slowing down: At the beginning of June, Ventas announced, that it is going to acquire American Realty Capital Healthcare REIT for a consideration of $2.6 billion in stock and cash.

The transaction would further broaden Ventas' facility footprint in the United States and add another 143 properties to its existing property portfolio.

Furthermore, Ventas announced at the same time, that it would acquire 29 senior living communities in Canada from Holiday Retirement for a consideration of $900 million. Ventas expects both transactions to be accretive to 2015 underlying FFO.

FFO and dividend growth
Both organic growth and acquisitions have fueled Ventas' FFO and dividend growth over the last couple of years. From 2000 to 2014 (based on an estimated full-year 2014 FFO of $4.34), Ventas increased its funds from operations by 10% annually and its dividends by 9%.


Source: Ventas Investor Presentation June 2014

Ventas' normalized FFO increased by 13% annually from $2.88 per share in 2010 to $4.14 per share in 2013. Its dividends rose from $2.14 per share to $2.74 over the same time period, which leads to a compound annual growth rate of 9%.

All the while, Ventas' normalized FFO handsomely covered the dividend payout. Ventas projects a 2014 payout ratio of 67% which will allow for generous shareholder remuneration as well as retention of cash to fund the health care REIT's expansion hunger.

With an estimated dividend payout of $2.90 (annualized) in 2014, Ventas offers investors an enjoyable 4.5% dividend yield. Investors buying today have a good shot at seeing a 5% dividend yield on a cost basis a year from now, if Ventas is able to sustain its dividend growth into 2015. Given its accretive acquisition of American Realty Capital Healthcare REIT, Ventas has even more potential to hike its dividends in the next couple of quarters.

The Foolish Bottom Line
Ventas is a big boy in the health care industry and its large, diversified property portfolio backs an ever increasing FFO and dividend stream.

Its recent acquisition of American Realty Capital Healthcare REIT further underscores Ventas' ambition to turbocharge growth and find accretive acquisition targets.

Ventas' FFO and dividend growth appeal to investors who are seeking regular income from a high-quality REIT determined to grow.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Kingkarn Amjaroen has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information